210 related articles for article (PubMed ID: 15012870)
1. [Usefulness of PSA and its fractions in the diagnosis of prostate cancer].
Filella X; Truan D; Alcover J; Molina R; Luque P; Coca F; Ballesta AM
Med Clin (Barc); 2004 Feb; 122(7):241-4. PubMed ID: 15012870
[TBL] [Abstract][Full Text] [Related]
2. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
3. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
5. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
6. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
[TBL] [Abstract][Full Text] [Related]
7. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
9. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
[TBL] [Abstract][Full Text] [Related]
10. Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer.
Tamimi W; Dafterdar R; Mansi M; Alsaad K; Alarifi SA
Br J Biomed Sci; 2010; 67(4):184-8. PubMed ID: 21294445
[TBL] [Abstract][Full Text] [Related]
11. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
12. The establishment and evaluation of a new model for the prediction of prostate cancer.
Wang Q; Li YF; Jiang J; Zhang Y; Liu XD; Li K
Medicine (Baltimore); 2017 Mar; 96(11):e6138. PubMed ID: 28296726
[TBL] [Abstract][Full Text] [Related]
13. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
14. Complexed prostate-specific antigen for the detection of prostate cancer.
Filella X; Truan D; Alcover J; Gutierrez R; Molina R; Coca F; Ballesta AM
Anticancer Res; 2004; 24(6):4181-5. PubMed ID: 15736470
[TBL] [Abstract][Full Text] [Related]
15. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
17. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
[TBL] [Abstract][Full Text] [Related]
18. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
Okegawa T; Noda H; Nutahara K; Higashihara E
Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
